Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Leuprorelin

Leuprorelin ▴ Leuprorelin (leuprolide acetate) is a luteinizing hormone-releasing hormone agonist used in the palliative treatment of advanced prostate cancer. This subcutaneous depot formulation of leuprorelin is available for administration as 7.5, 22.5, or 30mg once every 1, 3, or 4 months, respectively. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/leuprorelin-IDD30xRwyW
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403030-00008
Publisher site
See Article on Publisher Site

Abstract

▴ Leuprorelin (leuprolide acetate) is a luteinizing hormone-releasing hormone agonist used in the palliative treatment of advanced prostate cancer. This subcutaneous depot formulation of leuprorelin is available for administration as 7.5, 22.5, or 30mg once every 1, 3, or 4 months, respectively.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References